Evicenter
MarkdownMedical informationP&T meetings
Ficerafusp alfa (BCA101)

First-line recurrent or metastatic HPV-negative head and neck squamous cell carcinoma, in combination with pembrolizumab

Last updated
135 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatment

Heterogeneity of treatment effect

13 evidence topics · 10 sources

Confirmed response by CPS, tumor burden, and disease extent across the three dose cohorts
Subgroup, % (n/N)750 mg weekly (n=30)1500 mg weekly (n=28)2000 mg every 2 weeks (n=27)
CPS 1-19“73 (8/11)”“54 (7/13)”“57 (8/14)”
CPS 20 or greater“47 (9/19)”“53 (8/15)”“38 (5/13)”
Sum of target lesion diameters 50 mm or less“55 (11/20)”“53 (8/15)”“53 (9/17)”
Sum of target lesion diameters greater than 50 mm“60 (6/10)”“54 (7/13)”“40 (4/10)”
Sum of target lesion diameters greater than 70 mm“50 (2/4)”“43 (3/7)”“33 (2/6)”
Locoregional disease only“38 (6/16)”“62 (5/8)”“50 (7/14)”
Distant metastatic disease only“100 (5/5)”“29 (2/7)”“40 (2/5)”
Locoregional and distant metastatic disease“67 (6/9)”“62 (8/13)”“50 (4/8)”